drugset / Trial / NCT00799578

A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT00799578

Phase 1/2 Completed 13 enrolled Joel Lavine Raptor Pharmaceuticals Corp. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in patients.

Timeline

Start
2008-10
Primary completion
2009-06
Completion
2010-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cysteamine Unknown 1000 mg Oral

Indications